
|Articles|September 29, 2015
PRA Collaborates on Vaccine Studies
Advertisement
PRA Health Sciences (PRA) announced a collaboration with the Alliance for Multispecialty Research (AMR) to improve the efficiency of vaccine studies. AMR is a network of independently owned, geographically diverse, and experienced Clinical Research Centers of Excellence and along with PRA’s vaccine experience in Phase I-IV trials will facilitate identification of appropriate vaccine study populations, as well as address subject retention and trial conduct in this area.
Read the
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
5




